EXINI Diagnostics
We empower patients for better healthcare with Artificial IntelligenceMore than 20 years of experience in developing certified medical device software
EXINI Diagnostics AB was established in 1999 to develop and market AI methods for automated analysis of diagnostic images developed by a research group at Lund University. We have developed automated analysis platforms for PSMA, cardiac, brain and bone scans. More than 800 healthcare facilities worldwide, have selected our software solutions.
EXINI is a wholly owned subsidiary of Lantheus Holdings, Inc.
Products
aBSI
aPromise
CURE8
Pylarify AI
Areas of Expertise
Research
Software
Pharma service
Interested in partnering with EXINI?
What do the experts say about the future of AI in medical imaging?
Providing a quantifiable and reproducible assessment of PSMA uptake and distribution in the body is critical here to enable precision oncology in prostate cancer.
The quantification and standardization of PSMA scan reports is a major step forward to enhance the reproducibility and timeliness of scan interpretations.
Modern chess AI running on even modest hardware can easily defeat the greatest human grand masters. There’s no reason to think the eventual outcome will be any different with diagnostic imaging. PSMA-AI is a step towards that goal.
Artificial intelligence is essential to advance molecular imaging in cancer, to capture the power of MI for detection and quantitating molecular expression of individual tumor lesions within the prostate cancer patient.
News
New version released of aPROMISE
We have now released a new version of aPROMISE for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool...
New version released of PYLARIFY AI®
We have now released a new version of PYLARIFY AI® for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool...
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 EuropeanAssociation of Nuclear Medicine (EANM) Annual Meeting
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using PYLARIFY®...
EXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.
Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market. The clinical value proposition of the platform is to increase the...
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those...
EXINI Executes Agreement with Siemens Healthineers for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
As of November 2022, EXINI has entered into an agreement with Siemens Healthineers to integrate its artificial intelligence (AI) enabled software as a medical devices – aPROMISE™ (automated PROstate...
EXINI Executes Agreement with Bayer AG for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
As of November 2022, EXINI has entered into an agreement with Bayer AG to integrate its artificial intelligence (AI) enabled software as a medical devices – aPROMISE™ (automated PROstate Cancer...
EXINI Diagnostics AB (EXINI) collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC)
EXINI has entered into a collaboration with the PCCTC to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer. The PCCTC is a premier multicenter clinical research...
EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform....